89Sr和153Sm-EDTMP治疗鼻咽癌多发性骨转移瘤疗效的比较

目的 比较＾８９Ｓｒ和＾１５３Ｓｍ－ＥＤＴＭＰ治疗鼻咽癌（ｎａｓｏｐｈａｒｙｎｇｅａｌ ｃａｒｃｉｎｏｍａ，ＮＰＣ）多发性骨转移瘤的疗效。方法 从１９９７年５月到１９９９年３月，作者用＾８９Ｓｒ和＾１５３Ｓｍ－ＥＤＴＭＰ分别治疗ＮＰＣ多发性骨转移病人４５例和６８例。根据治疗前后骨痛缓解和生活质量的情况决定疗效，同时比较其病灶摄取放射性变化，观察开始起效的时间，对病人血清ＶＣＡ－ＩｇＡ、ＥＡ－ＩｇＡ

Comparison of treatment result with 89Sr and 153Sm-EDTMP in NPC patients with bone metastases

Objective: To compare treatment result of ~(89)Sr and ~(153)Sm-EDTMP in nasopharyngeal carcinoma (NPC) patients with bone metastases. Methods: NPC patients with bone metastases were treated using ~(89)Sr (45 cases) or ~(153)Sm-EDTMP (68 cases). The effectiveness was determined by pain relief and life quality improvement, changes of bone morrow function and VCA-IgA, EA-IgA level. Results: The response rate to ~(89)Sr and ~(153)Sm-EDTMP was 86.7% and 88.2%. respectively (P>0.05). The effective period following treatment was 11.0 and 7.2 days, and bone morrow repression rate was 22% and 42%, respectively. These differences were significant (P<0.02). The influence to serum VCA-IgA and EA-IgA level, and radioactive uptake of bone lesion ROI following ~(89)Sr or ~(153)Sm-EDTMP treated was significantly different (P <0.05). Conclusions: ~(89)Sr and ~(153)Sm-EDTMP can relief bone pain and improve patient's life quality. ~(153)Sm-EDTMP may repress bone metastases stronger than ~(89)Sr, and can decrease patient's serum VCA-IgA and EA-IgA level, but the blood toxity is also more serious than ~(89)Sr.